GSK buyback lifts treasury shares to 232.8 m in July 2025 filing

Rhea-AI Filing Summary

On 18 Jul 2025, GSK plc bought back 505,771 ordinary shares (nominal 31¼ p) through Merrill Lynch International as part of its previously announced non-discretionary buy-back programme.

The shares were purchased between 1,319.0 p and 1,360.5 p, with a volume-weighted average price of 1,344.42 p. Since the programme commenced on 4 Jun 2025, GSK has repurchased 14,683,084 shares.

Following this latest transaction, the company now holds 232,817,467 shares in treasury, representing 5.70 % of total voting rights. Shares outstanding (excluding treasury) stand at 4,082,566,813, which investors should use as the denominator when assessing disclosure thresholds under the FCA’s DTR rules.

The filing contains no new earnings or guidance; it solely updates the market on the progress of GSK’s authorised share-repurchase programme.

Positive

• Continued execution of authorised share-buyback with 14.7 m shares repurchased since 4 Jun 2025, reflecting ongoing capital return commitment.

Negative

• None.

Insights

Equity Analyst

TL;DR – Routine buy-back update; modestly shareholder-friendly, limited valuation impact.

The purchase of 505.8k shares at a 1,344p VWAP marginally shrinks the float and signals continued cash allocation to shareholder returns. Treasury holdings now equal 5.7 % of voting rights, suggesting steady execution of the June-launched programme (14.7 m shares to date). Given GSK’s >£60 bn market cap, the incremental reduction (<0.02 % of shares) is too small to materially alter EPS or valuation in the near term. The disclosure is therefore neutral-to-slightly-positive for equity holders, reaffirming management’s commitment to capital return without altering fundamentals.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of July 2025

Commission File Number 001-15170

GSK plc

(Translation of registrant's name into English)

79 New Oxford Street, London, WC1A 1DG

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

Transaction in own shares

GSK plc (the "Company") announces today acting through its corporate stockbroker, Merrill Lynch International (the "Broker"), it has purchased the following number of the Company's ordinary shares of 31¼ pence each.

Date of purchase:	18 July 2025
Aggregate number of ordinary shares of 31¼ pence each purchased:	505,771
Lowest price paid per share (GBp):	1,319.00p
Highest price paid per share (GBp):	1,360.50p
Volume-weighted average price paid per share (GBp):	1,344.42p

The purchased shares will be held as Treasury shares.

Such purchase forms part of the Company's existing buyback programme and was effected pursuant to the non-discretionary agreement entered into with the Broker on 4 June 2025, as announced on 4 June 2025. Since 4 June 2025 the Company has purchased 14,683,084 ordinary shares.

Following the above purchase, the Company will hold 232,817,467 ordinary shares in treasury and have 4,082,566,813 ordinary shares in issue (excluding Treasury shares).

The total number of voting rights in the Company is 4,082,566,813. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

The Company confirms that, in accordance with DTR 5.5.1R, following the above purchase the percentage of voting rights attributable to the ordinary shares held in treasury is 5.70 per cent.

Detailed information of the individual trades made by the Broker on the London Stock Exchange and the CBOE Europe Limited recognised investment exchange (through its order books having market identification codes CHIX or BATE) as part of the buyback programme can be found at:

http://www.rns-pdf.londonstockexchange.com/rns/7518R_1-2025-7-18.pdf

                                               Ends

GSK enquiries
Media:	Tim Foley	+44 (0) 20 8047 5502	(London)
	Kathleen Quinn	+1 202 603 5003	(Washington DC)
Investor Relations:	Constantin Fest	+44 (0) 7831 826525	(London)
	James Dodwell	+44 (0) 20 8047 2406	(London)
	Mick Readey	+44 (0) 7990 339653	(London)
	Steph Mountifield	+44 (0) 7796 707505	(London)
	Jeff McLaughlin	+1 215 751 7002	(Philadelphia)
	Frannie DeFranco	+1 215 751 3126	(Philadelphia)

Cautionary statement regarding forward-looking statements

GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the "Risk Factors" section in GSK's Annual Report on Form 20-F for 2024, and GSK's Q1 Results for 2025.

Registered in England & Wales:

No. 3888792

Registered Office:

79 New Oxford Street

London

WC1A 1DG

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GSK plc

(Registrant)

Date: July 21, 2025

By:/s/ VICTORIA WHYTE

--------------------------

Victoria Whyte

Authorised Signatory for and on

behalf of GSK plc

FAQ

How many GSK (GSK) shares were repurchased on 18 July 2025?

GSK bought back 505,771 ordinary shares on 18 July 2025.

What was the average price paid by GSK for the repurchased shares?

The volume-weighted average price was 1,344.42 p per share.

How many shares has GSK repurchased since 4 June 2025?

The company has bought back 14,683,084 ordinary shares since the programme began.

What percentage of voting rights do GSK treasury shares now represent?

Treasury shares represent 5.70 % of total voting rights.

How many GSK shares are currently in issue excluding treasury shares?

There are 4,082,566,813 ordinary shares in issue (ex-treasury).